Close mobile menu×
Close mobile menu

Justine Kahn, MD, MS

Board Certifications: 
Pediatric Hematology-Oncology, Pediatrics
Accepting New Patients
Treats Children
Profile Hero

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Board Certifications

  • Pediatric Hematology-Oncology
  • Pediatrics

Education & Training

  • MD, Icahn School of Medicine at Mount Sinai
  • MS, Columbia University, Mailman School of Public Health
  • 2010 Mount Sinai School of Medicine
  • Residency: Mount Sinai Medical Center
  • Residency: 2013 Mount Sinai Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: 2016 NewYork-Presbyterian/Columbia University Medical C

Honors & Awards

Transform KL2 Scholars Mentored Career Development Program, National Institute of Health Clinical and Translational Science Award, Columbia University Irving Institute for Clinical and Translational Research

Lymphoma Research Foundation (LRF): Adolescent/Young Adult Lymphoma Correlative Studies Grant

Lymphoma Research Foundation (LRF) Clinical Research Mentoring Program

Columbia Presbyterian 2016 Metropolitan Fund Fellowship Award, Department of Pediatrics, NY-Presbyterian/Columbia University Medical Center, New York

Alpha Omega Alpha Honor Medical Society, ICAHN School of Medicine at Mount Sinai Hospital, New York

Arnold P. Gold Humanism Award in Pediatrics, ICAHN School of Medicine at Mount Sinai Hospital, New York

About Justine Kahn

Dr. Justine Kahn is a Pediatric Oncologist and a clinical investigator specializing in survival outcomes, cancer care delivery, and health equity in children and adolescent/young adults (AYA) with Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Dr. Kahn received her MD from the Icahn School of Medicine at Mount Sinai in New York and completed her Pediatric Residency at Mount Sinai Kravis Children’s Hospital in New York. Dr. Kahn completed her Clinical Fellowship in Pediatric Hematology/Oncology at Columbia University Medical Center. While in residency, Dr. Kahn was elected to Alpha Omega Alpha, the national medical honor society which recognizes high educational achievement. During her fellowship, Dr. Kahn served as a Postdoctoral Research Fellow in Cancer-Related Population Sciences supported by the National Cancer Institute for her work in cancer care delivery, health equity, and health outcomes research. Upon graduation from fellowship, Dr. Kahn joined the Pediatric Hematology/Oncology Division at Columbia University Medical Center as an Oncology Instructor and Attending Physician in 2016. She is currently involved in patient care, clinical trials research, and health outcomes research. In June of 2018, Dr. Kahn obtained a Master of Science in Patient Oriented Research at the Columbia Mailman School of Public Health. In July of 2018 she became an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology/Stem Cell Transplantation.

Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer.

Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma. She serves as CUMC site Principal Investigator for the DFCI ALL Consortium.

Academic Titles

  • Instructor in Pediatrics

Committee/Societies/Council Memberships

Co-Leader, Disparities Working Group, Hodgkin Lymphoma Committee, NCI-Supported Children’s Oncology Group

Member,�Hodgkin Lymphoma Committee, NCI-Supported Children's Oncology Group

Member and CUMC Site Principal Investigator,�Dana-Farber Cancer Institute ALL Consortium

Member, Histiocyte Society

Member, American Society of PediatricHematology/Oncology

Member, American Society of Clinical Oncology

Member, American Society of Hematology

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Morgan Stanley Children's Hospital

Gender

  • Female

Insurance Accepted

For billing questions, please call (212) 304-7250.

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032

Research

“Of all the forms of inequality, injustice in health care is the most shocking and inhumane.” - Martin Luther King Jr.

Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer.

Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma. She serves as CUMC site Principal Investigator for the DFCI ALL Consortium.

Research Interests

  • Adolescent and young adult (AYA) oncology
  • Cancer care delivery
  • Health outcomes and survival disparities
  • Leukemia and lymphoma
  • Social determinants of health
  • Survivorship

Selected Publications

Kahn JM*, Kelly KM. Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborativescienceandmultidisciplinarycare.PediatricBlood&Cancer.2018Mar30:e27033.doi: 10.1002/pbc.27033. [Epub ahead of print] Review. PubMed PMID:29603618

Kahn JM*, Cole PD, Blonquist TM, Stevenson K, Jin Z, Barrera S, Davila R, Roberts E, Neuberg DS, Athale UH, Clavell LA, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Sallan SE, Silverman LB, Kelly KM. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. Pediatric Blood & Cancer. 2018 Mar;65(3). doi:10.1002/pbc.26871.PubMedPMID:29090520; PubMed Central PMCID: PMC5766393.

Kahn JM*,Ozuah NW, Dunleavy K, Henderson TO, Kelly K, LaCasce A. Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. Blood Advances.2017Oct10;1(22):1945-1958.doi:10.1182/bloodadvances.2017008748.PubMedPMID: 29296842; PubMed Central PMCID: PMC5728148.

Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, Sosna J,Bhatia M, Kung AL,George D, Garvin JH, Satwani P. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood & Marrow Transplantation.2016 Sep;22(9):1646-1653. doi: 10.1016/j.bbmt.2016.05.014. Epub 2016 May 29. PubMed PMID: 27252110; PubMed Central PMCID: PMC5496767

Kahn JM*, Athale UH, Clavell LA, Cole PD, Leclerc JM, Laverdiere C, Michon B, Schorin MA,Welch JJ, Sallan SE, Silverman LB, Kelly KM. How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic. Journal of Pediatric Health Care. 2017 Jan - Feb;31(1): e1-e6. doi: 10.1016/j.pedhc.2016.06.004. PubMed PMID: 27461368; PubMed Central PMCID: PMC5154954

Kahn JM*,KeeganTH,TaoL,AbrahãoR,BleyerA,VinyAD.Racialdisparitiesinthesurvivalof American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016 Sep 1;122(17):2723-30. doi: 10.1002/cncr.30089. PubMed PMID: 27286322; PubMed Central PMCID:PMC4992431

Kolb M, Offer K, Jin Z, Kahn J, Bhatia M, Kung AL, Garvin JH, George D, Satwani P. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood & Marrow Transplantation. 2016 May;22(5):957-61. doi: 10.1016/j.bbmt.2016.02.005. PubMed PMID: 26880117; PubMed Central PMCID:PMC5496769

Al Mulla N, Kahn JM*, Jin Z, Qureshi M, Karamehmet E, Yoon-Jeong Kim G, Levinson AL, Bhatia M, GarvinJ H, George D, Kung AL, SatwaniP.SurvivalImpactofEarlyPost-Transplant Toxicitiesin Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Non-Malignant Diseases: Recognizing Risks and Optimizing Outcomes.Biology of Blood & Marrow Transplantation. 2016 Aug;22(8):1525-1530. doi: 10.1016/j.bbmt.2016.05.012. PubMed PMID: 27223110; PubMed Central PMCID:PMC5496771

Satwani P, Kahn J, Jin Z. Making strides and meeting challenges in pediatric allogeneic hematopoietic cell transplantation clinical trials in the United States: Past, present and future.Contemporary Clinical Trials. 2015 Nov;45(Pt A):84-92

Kahn JM*,Hamburger-Smilow, E,Bhatia, M.Hematopoietic cell transplantation and sickle cell disease: An option for everyone? Current Pediatrics Reports. 2015 June;3(2):146-153